Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Vertex Pharmaceuticals (NQ: VRTX ) 480.30 -2.34 (-0.48%) Streaming Delayed Price Updated: 4:00 PM EDT, Aug 27, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Headline News about Vertex Pharmaceuticals < Previous 1 2 3 4 5 6 7 8 9 ... 46 47 Next > 3 Biotech Stocks Set to Double by 2028 April 20, 2024 These are three of the top biotech stocks set to double by 2028. Add them to your portfolio to maximize your potential gains. Via InvestorPlace Is Vertex Pharmaceuticals Stock a Millionaire Maker? April 19, 2024 Does this pharma stock have the potential to turn a $25,000 investment into seven figures or more? Via The Motley Fool Tesla To $123? Here Are 10 Top Analyst Forecasts For Thursday April 18, 2024 Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Via Benzinga Does This Acquisition Make Vertex Pharmaceuticals Stock a Buy? April 18, 2024 The biotech just added another potential growth driver to its pipeline. Via The Motley Fool If You Invested $1000 In This Stock 10 Years Ago, You Would Have $6,000 Today April 16, 2024 Via Benzinga The Analyst Landscape: 16 Takes On Vertex Pharmaceuticals April 12, 2024 Via Benzinga Vertex Pharmaceuticals: Buy, Sell, or Hold? April 11, 2024 The stock hasn't made for a great buy this year, but is Vertex worth investing in for the long run? Via The Motley Fool 1 Top Growth Stock to Buy and Hold Forever March 31, 2024 This drugmaker looks unstoppable. Via The Motley Fool Here's (at Least) 1 new Reason to Buy Vertex Pharmaceuticals Stock April 15, 2024 Vertex just laid claim to an asset that might be very valuable. Via The Motley Fool Could This Stock Be the Next Biotech Buyout? April 13, 2024 Vertex Pharmaceuticals' $4.9 billion purchase of Alpine Immune Sciences probably won't be the last acquisition of a company focused on kidney disease. Via The Motley Fool Stock Market Sends Mixed Signals; Nvidia, Inflation, Mideast Fears In Focus: Weekly Review April 12, 2024 The stock market gave some bullish signs, with Nvidia rebounding, but the indexes generally fell for the week on inflation and Mideast fears. Via Investor's Business Daily Topics Economy Exposures Interest Rates Vertex's Alpine Acquisition: Unpacking Analyst Predictions on Povetacicept's Potential Impact April 11, 2024 Vertex Pharmaceuticals to acquire Alpine Immune Sciences for $4.9 billion, expanding into nephrology with promising APOL1-mediated kidney disease treatments. Analysts foresee significant revenue growth... Via Benzinga Stocks Bounce Back With Tech, Gold Gaining After Modest Producer Inflation Data: What's Driving Markets Thursday? April 11, 2024 Investors can breathe a sigh of relief on Thursday as last month’s Producer Price Index (PPI) inflation turned out slightly lower than expected, albeit with some caveats across different measures... Via Benzinga Topics Economy Exposures Interest Rates Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for April 2024 April 11, 2024 In a stock picker’s market, here are three biotech stocks analysts believe have a chance to outperform the market in 2024. Via InvestorPlace Raymond James Just Raised Its Price Target on Nvidia (NVDA) Stock April 11, 2024 Nvidia stock is on the move Thursday after shares of NVDA got an increased price target of $1,100 from Raymond James analysts. Via InvestorPlace Apple Spyware Warning: What to Know About ‘Mercenary Spyware Attack’ Alerts April 11, 2024 An Apple spyware warning has been sent to iPhone owners in 92 states as they have been targeted by a mercenary spyware attack. Via InvestorPlace The $5 BILLION Reason Alpine Immune Sciences (ALPN) Stock Is Up 30% Today April 11, 2024 Vertex hopes Alpine's drug can be tested on other conditions beyond the one entering Phase 3 trial for a kidney disease. Via InvestorPlace Biotech Stocks Heat As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores Options April 11, 2024 Novartis snagged a licensing deal with Arvinas worth up to $1.16 billion, while Janux is said to be exploring its options. Via Investor's Business Daily Vertex Pharmaceuticals Moves Beyond $10B Cystic Fibrosis Franchise, Pays Around $5B For Kidney Disease Player Alpine Immune April 11, 2024 Vertex Pharmaceuticals to acquire Alpine Immune Sciences for $4.9 billion in cash. Povetacicept, a potent dual antagonist of BAFF and APRIL, shows promise in IgA nephropathy. Transaction expected to... Via Benzinga Wall Street Braces For Another Red Day Ahead Of More Inflation Data While Bitcoin Holds Above $70K: Analyst Sees Any Pullback As 'Phenomenal Buying Opportunity' April 11, 2024 The negative mood on Wall Street may persist as investors await the release of another inflation report, which will have significant implications for the near-term trend in cons Via Benzinga Topics Economy Exposures Interest Rates Vertex Pharmaceuticals Nabs Alpine Immune Sciences In $4.9 Billion Deal April 10, 2024 The companies expect the deal to close later this quarter. Via Investor's Business Daily This Growth Stock Is One Step Closer to Launching a New Blockbuster: Time to Buy? April 09, 2024 This innovative machine rolls on. Via The Motley Fool Jim Cramer Was Upset At This Hostile Takeover, But 'They Fixed The Situation. Stock's Been A Horse' April 09, 2024 On CNBC’s "Mad Money Lightning Round," Jim Cramer said he prefers Abbott Laboratories (NYSE: ABT) over Via Benzinga 3 High-Growth Biotech Stocks Investors Shouldn’t Sleep On in April April 09, 2024 These high-growth biotech stocks are certainly worth considering for investors looking for market-beating returns in the long-term. Via InvestorPlace Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon. April 09, 2024 These companies are close to launching new products that could supercharge revenue. Via The Motley Fool Got $1,000? 2 Bulletproof Stocks to Buy in 2024 and Hold for the Long Haul April 05, 2024 These businesses are booming. Via The Motley Fool Missed the "Magnificent Seven"? Try Buying These 3 Forever Stocks Instead April 01, 2024 All three companies have very long runways for growth ahead. Via The Motley Fool Meet The "Magnificent Seven" of Healthcare Stocks April 01, 2024 The tech sector doesn't have a monopoly on magnificent corporations. Via The Motley Fool 2 Rock-Solid Growth Stocks to Buy Right Now and Hold for at Least 5 Years March 31, 2024 Great businesses are here to stay. These are two excellent examples. Via The Motley Fool 3 Unstoppable Stocks to Buy Hand Over Fist in April March 30, 2024 These stocks have exceptionally bright prospects. Via The Motley Fool < Previous 1 2 3 4 5 6 7 8 9 ... 46 47 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.